Schering-Plough Announces New Drug Application For Sugammadex Assigned Priority Review Status By U.S. FDA
Schering-Plough Corporation (NYSE: SGP) announced that the U.S. Food and Drug Administration (FDA) has assigned priority review status to the company’s New Drug Application (NDA) for sugammadex. Sugammadex is specifically designed to reverse the effects of certain muscle relaxants, marketed in the United States as ZEMURONŽ (rocuronium bromide) and vecuronium bromide. Muscle relaxants are used as part of general anesthesia during surgical procedures.
More: continued here